ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial (Q28365255)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial	scientific article

Statements

scholarly article

0 references

ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial (English)

0 references

11

object named as

D C Linch

0 references

author name string

B W Hancock

1

0 references

W M Gregory

2

0 references

M H Cullen

3

0 references

G V Hudson

4

0 references

A Burton

5

0 references

P Selby

6

0 references

K A Maclennan

7

0 references

A Jack

8

0 references

E M Bessell

9

0 references

P Smith

10

0 references

language of work or name

0 references

publication date

18 May 2001

0 references

British Journal of Cancer

0 references

84

0 references

10

0 references

1293-300

0 references

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

20 March 2017

Report of the Committee on Hodgkin's Disease Staging Classification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

20 March 2017

Twenty years of MOPP therapy for Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

20 March 2017

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

20 March 2017

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

20 March 2017

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

29 September 2017

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

29 September 2017

Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

29 September 2017

Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

29 September 2017

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

29 September 2017

British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

29 September 2017

Chemotherapy for advanced Hodgkin's disease: conclusions from the Southeastern Cancer Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

2 June 2018

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

2 June 2018

Combination chemotherapy in generalized Hodgkin's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

20 June 2018

Rationale for the use of alternating non-cross-resistant chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

27 November 2018

Alternating drug combinations in the treatment of advanced Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363648

27 November 2018

Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/11355937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?

1 reference

https://pubmed.ncbi.nlm.nih.gov/11355937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11355937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11355937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/11355937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B

1 reference

https://pubmed.ncbi.nlm.nih.gov/11355937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP

1 reference

https://pubmed.ncbi.nlm.nih.gov/11355937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/11355937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1054/BJOC.2001.1778

0 references

Dimensions Publication ID

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28365255&oldid=2175249870"